 Please join the keynote speakers, Leroy Hood, MD, PhD, and Ralph Snyderman, MD, and share their insights on the latest development and the future of personalized medicine.
Leroy Hood, MD, PhD, is the president and founder of the Institute of Systems Biology. Dr. Hood is a world-renowned immunologist and technologist. His professional career began at Caltech where he and his colleagues pioneered four instruments — the DNA gene sequencer and synthesizer, and the protein synthesizer and sequencer — which comprise the technological foundation for contemporary molecular biology. In particular, the DNA sequencer has revolutionized genomics by allowing the rapid automated sequencing of DNA, which played a crucial role in contributing to the successful mapping of the human genome during the 1990s. In 1992, Dr. Hood moved to the University of Washington as founder and Chairman of the cross-disciplinary Department of Molecular Biotechnology. In 2000, he co-founded the Institute for Systems Biology in Seattle, Washington to pioneer systems approaches to biology and medicine.
Dr. Hood has received numerous awards including the prestigious 2004 Biotechnology Heritage Award and the 2003 Association for Molecular Pathology (AMP) Award for Excellence in Molecular Diagnostics. In 2006 he received the Heinz Award in Technology, the Economy and Employment for his extraordinary breakthroughs in biomedical science at the genetic level. In 2007 he was elected to the Inventors Hall of Fame (for the automated DNA sequencer). His research has focused on the study of molecular immunology, biotechnology, and genomics. He has published more than 600 peer-reviewed papers, received 14 patents, and has co-authored textbooks in biochemistry, immunology, molecular biology, and genetics and systems biology. In addition, he coauthored with Dan Keveles a popular book on the human genome project-The Code of Codes.
Dr. Hood is a member of the National Academy of Sciences, the American Philosophical Society, the American Academy of Arts and Sciences, the Institute of Medicine and the National Academy of Engineering. Indeed, Dr. Hood is one of 7 (of more than 6000) scientists elected to all three academies (NAS, NAE and IOM). He has also played a role in founding more than 14 biotechnology companies, including Amgen, Applied Biosystems, Systemix, Darwin and Rosetta. He is currently pioneering systems medicine and the systems approach to disease.
return to top
|
 Ralph Snyderman, MD, is a chancellor emeritus, Duke University, and founder and chairman of Proventys, Inc. From 1989 to 2004, he served as chancellor for Health Affairs and dean of the School of Medicine and led the transition of this excellent medical center into an internationally recognized leader of academic medicine. During his tenure, Dr. Snyderman oversaw the establishment of the Duke Clinical Research Institute, the Institute for Genome Sciences and Policy, and the Duke University Health System. He has played a leading role in the conception and development of prospective care, a novel approach to personalized health and an evolving model of national health care. In 2004, after stepping down as chancellor, Dr. Snyderman founded Proventys Inc., a healthcare technology company committed to advancing personalized medicine through validated predictive diagnostics delivered at the point-of-care. He has received numerous awards, including the 2007 Leadership in Personalized Medicine Award in 2007 and the 2008 North American Healthcare Lifetime Achievement Award.
Dr. Snyderman accepted his first faculty appointment at Duke in 1972 and became chief of the Division of Rheumatology and Immunology in 1975, and in 1984, he was the Frederic M. Hanes Professor of Medicine and Immunology. Dr. Snyderman is internationally recognized for his contribution in inflammation research. He has published more than 350 manuscripts as well as numerous books. In 1987, Dr. Snyderman left Duke to join Genentech, Inc., a biomedical technology firm in San Francisco, CA, as vice president for medical research and development. A year later he was promoted to senior vice president. While at Genentech, he led the development and licensing of several novel therapeutics and supervised 300 staff members working in pharmacology, clinical research and regulatory affairs.
return to top |
